# V1 Empirics Check — openai/gpt-5.4 (Variant C)

**Model:** openai/gpt-5.4
**Variant:** C
**Date:** 2026-03-13T01:41:26.066471

---

## 1. Idea Fidelity

The paper only partially pursues the original idea in the manifest, and the departures matter for identification and interpretability.

First, the data source changed in an important way. The manifest proposed CDC WONDER Expanded Natality tabulations with a richer composition vector: marital status, Medicaid payment, education, NICU, prenatal care adequacy, etc. The paper instead uses Kids Count state-year aggregates with only four composition outcomes. That is a much thinner test of the “composition” question and effectively drops the most policy-relevant margins in the original idea—especially Medicaid payment, maternal education, and prenatal care. As written, the paper does not really deliver on “the composition of newborns” so much as “four coarse state-year birth shares.”

Second, the treatment coding and timing are looser than in the manifest. The original idea emphasized staggered effective dates and a careful distinction between total bans and gestational limits. The paper collapses these into a single treatment indicator despite very different treatment intensities and legal durability. It also annualizes treatment so aggressively that almost all 2022 changes are pushed into 2023, leaving essentially one post-treatment birth year. That may be unavoidable with annual data, but then the paper should be framed as an early reduced-form short-run exercise, not a definitive test of compositional effects.

Third, the original idea proposed supplementary marriage evidence and mechanism decomposition. Those pieces disappear. Given that the unmarried-birth margin is central to the Akerlof-Yellen-Katz framing, the omission is notable.

So: the paper follows the broad spirit of the manifest, but it implements a materially weaker design than originally proposed.

## 2. Summary

This paper asks whether post-*Dobbs* abortion restrictions changed not just the number of births, but the composition of births. Using a state-year panel and staggered DiD methods, it finds a positive effect on total births and essentially null effects on the shares of unmarried, low-birthweight, preterm, and teen births.

The question is important and the null result could be interesting. But in its current form the paper does not yet establish a persuasive economically meaningful null, because the outcome measures are too aggregated, the treatment is too coarse, and some of the specification diagnostics point to nontrivial identification problems.

## 3. Essential Points

**1. The identifying variation is too weak, and the pre-trend evidence is not reassuring.**  
You have only one clearly post-treatment birth year for most treated states, with treatment timing compressed into 2023/2024 at the annual level. That is a very demanding setting in which to claim informative nulls on composition. More importantly, your own event-study and placebo results raise concerns: significant pre-treatment coefficients for several outcomes, and a significant placebo effect for unmarried births. I do not agree with the paper’s current dismissal of these as benign oscillations. With only 51 state clusters and highly persistent state-level shares, those diagnostics should materially lower confidence in the design, especially for the marriage-related outcome.

**2. The magnitudes and inference need to be interpreted much more carefully.**  
The 1.5% birth effect is somewhat smaller than Myers et al. but plausibly in range given the broader treatment definition and annual aggregation. The composition coefficients are tiny, but the paper overstates what that means. A null at the state-year share level does not imply no meaningful compositional change in the marginal births. If bans increase births by 1.5% and the added births are only modestly more disadvantaged, the implied change in statewide birth shares could still be mechanically small. The paper needs a back-of-the-envelope minimum-detectable-effect or “what selection pattern would this design be able to detect?” exercise. Right now, “no statistically significant change in shares” is being interpreted too strongly.

**3. The outcome and treatment definitions are too coarse for the question posed.**  
Lumping six-week bans, 15-week bans, and total bans into one treatment is hard to defend substantively. Likewise, restricting composition to four state-level shares is too limited to support the paper’s broad conclusions about fiscal and health implications. The strongest outcomes from the original idea—Medicaid-financed births, maternal education, and prenatal care—are missing, yet the conclusion speaks to public expenditure and risk composition. That is an overreach relative to the evidence presented.

## 4. Suggestions

The paper is asking a good question, and I think there is a publishable short paper here, but it needs to become more disciplined and more transparent about what can and cannot be learned from these data.

**Most importantly, upgrade the data if at all possible.** The current Kids Count panel is probably too aggregated for this question. The original CDC WONDER Expanded Natality plan is much better suited to an AER: Insights-style paper because it would let you examine the margins that are most likely to move and most meaningful economically: Medicaid payer, maternal education, race/ethnicity, parity, prenatal care, and possibly NICU admission if consistently available. If access or automation constraints prevent that, then the paper should be repositioned as a very preliminary aggregate-state null rather than a broad statement about the “composition of newborns.”

**Clarify the estimand mechanically.** Readers need help understanding why composition effects could be hard to detect in shares even if the marginal births differ. A simple decomposition would help:
\[
\Delta \text{Share} \approx \frac{\Delta B_g - s_0 \Delta B}{B_0+\Delta B}
\]
where \(B_g\) is births in group \(g\), \(B\) total births, and \(s_0\) the baseline share. This would let you show that even meaningful selection among marginal births may generate only modest changes in statewide shares when total births rise by only 1–3 percent. That would both discipline the interpretation and make the paper more economically coherent.

**Add power / minimum-detectable-effect calculations.** This is essential for a null paper. For each outcome, state what size compositional shift among marginal births your design could detect with 80% power. For example: if births rise by 1.5%, what difference in the unmarried share of marginal births versus inframarginal births would translate into a detectable change in the statewide unmarried share? Without that exercise, the reader cannot tell whether the null is informative or just noisy.

**Rework the treatment definition.** At a minimum, separate: (i) total/near-total bans, (ii) six-week bans, and (iii) 12–15 week limits. These are not the same treatment. The current pooled specification likely attenuates effects and muddies interpretation. I would present total bans as the main specification and gestational limits as secondary heterogeneity. Also address legal instability: some bans were enjoined, reinstated, or partially operative. A binary annual treatment may misclassify effective access. Even a crude “share of the year under ban” measure would be preferable.

**Handle Texas/SB8 more seriously.** You mention it in robustness, but SB8 is not just an outlier; it is a major design complication. Texas experienced a substantial abortion restriction beginning in September 2021, so its trends are unlikely to fit cleanly into the post-*Dobbs* treatment coding. I would either (a) exclude Texas from the baseline and show it as a separate case, or (b) recode treatment to reflect SB8 exposure in the births data. Right now the paper acknowledges the issue but does not integrate it into the main design.

**The standard errors are probably acceptable as a baseline, but they are not enough on their own.** With roughly 51 clusters, state clustering is standard and likely fine asymptotically, but given the small number of treated states and the highly aggregated state-year panel, I would like to see wild-cluster bootstrap p-values or randomization-inference-style permutation tests. This is especially important for the quantity result and for any interpretation of the unmarried-birth null, where placebo evidence is unfavorable. Also report simultaneous confidence bands for the event study, not pointwise stars.

**Be much more cautious in discussing pre-trends.** Significant leads and a significant placebo on unmarried births should not be brushed aside as “consistent with sampling variation.” That is not credible language in an empirical paper. A better framing is: “For unmarried births, diagnostics indicate meaningful differential pre-trends, so we treat those estimates as inconclusive.” That would actually strengthen the paper’s credibility.

**Consider border-state contamination explicitly.** Never-treated states are not clean controls if they absorb abortion travel and perhaps associated births or changes in pregnancy resolution. The paper currently notes travel as a mechanism attenuating treatment effects, but it could also affect the comparison group. One useful check would be to exclude states bordering ban states, or at least re-estimate using only distant access states as controls. Another would be to interact treatment with distance to the nearest access state, though that likely requires county-level data.

**The economic interpretation should be tightened.** The sentence converting the unmarried-share coefficient into “38 additional births to unmarried mothers” is not a persuasive way to discuss economic significance. It confuses changes in shares with levels and understates uncertainty. More importantly, your policy question is not whether the coefficient sounds small in raw numbers, but whether the design rules out composition changes large enough to matter fiscally or clinically. Frame the discussion around detectable effect sizes and implied changes in payer mix or neonatal risk, ideally using richer outcomes.

**The quantity estimate deserves more benchmarking.** You say it is consistent with Myers et al., but your 1.5% estimate is materially below 2.3%, while your TWFE estimate is 3.1%. That spread is large. Explain why. Is it because you include gestational-limit states, use annual births rather than monthly, code treatment by birth-year exposure, or use a different control set? A short reconciliation exercise would increase confidence that the design is behaving sensibly.

**The event-study table should be simplified and improved.** A table with many starred pre-period coefficients is hard to digest and, frankly, visually hurts the paper. A figure with confidence intervals would be much better. If only \(k=0\) exists post-treatment, say so clearly. Right now the dynamic design sounds richer than it is.

**Do not overclaim on fiscal implications.** With only four outcomes, none directly tied to payer mix or maternal socioeconomic status except marital status and teen status, the paper cannot credibly conclude that fiscal multipliers are “smaller than feared.” That claim would require evidence on Medicaid-financed births, maternal education, or neonatal intensive utilization. Tone this down unless you add those outcomes.

**Two framing options would both improve the paper.**
1. **Stronger data, same question:** move to CDC WONDER natality tabulations, expand outcomes, keep the current basic design, and present the paper as the first broad composition analysis.  
2. **Same data, narrower question:** present this as an early evidence note showing that aggregate state-year adverse birth shares did not move detectably in 2023, while being explicit that the design cannot rule out meaningful selection among marginal births.

I would encourage the first option if feasible; it fits the original idea and would make the contribution much clearer.

Overall, I think the paper has a worthwhile question and a potentially interesting result, but the current version is too quick to interpret “small, insignificant changes in aggregate shares” as “no meaningful compositional response.” Tightening the design, broadening the outcomes, and being more honest about the identification limits would substantially improve it.
